RLYP Description — Relypsa, Inc
Relypsa is a biopharmaceutical company focused on the discovery, development and commercialization of polymer-based drugs to treat that are overlooked and undertreated, but that can have an effect on patients' lives and even be life-threatening. Co.'s product candidate, Veltassa® (patiromer) for oral suspension (Veltassa), is for the treatment of hyperkalemia. Hyperkalemia is a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Veltassa is a non-absorbed, high capacity potassium binding polymer. The active ingredient in Veltassa is a cross-linked polymeric bead that includes calcium as a counterion.